Literature DB >> 9814595

CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis.

J D Laman1, M De Boer, B A Hart.   

Abstract

The interactions of CD40 and CD40L have been known for some time to critically regulate B-cell responses with respect to proliferation, isotype switching, antibody production, and memory formation. More recent findings demonstrated that CD40 can be expressed on several other antigen-presenting cell (APC) types such as macrophages, dendritic cells, and fibroblasts. This expression of CD40 regulates T-cell-APC interaction and is centrally involved in a wide array of inflammatory events. Here, currently available data are reviewed demonstrating that CD40-CD40L interactions are operational in two chronic inflammatory clinical conditions, namely, multiple sclerosis and atherosclerosis. The functional correlates of these interactions are discussed in the light of recent other findings, shedding light on the multiple effects of CD40-CD40L interactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814595      PMCID: PMC2276030          DOI: 10.1155/1998/69628

Source DB:  PubMed          Journal:  Dev Immunol        ISSN: 1026-7905


  11 in total

1.  Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.

Authors:  Yun-Fang Zhang; Xun-Liang Zou; Jun Wu; Xue-Qing Yu; Xiao Yang
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 2.  Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis.

Authors:  Isabelle Pastor Bandeira; André Eduardo de Almeida Franzoi; Giulia Murillo Wollmann; Washigton Luiz Gomes de Medeiros Junior; Wesley Nogueira Brandão; Jean Pierre Schatzmann Peron; Jefferson Becker; Osvaldo José Moreira Nascimento; Marcus Vinícius Magno Gonçalves
Journal:  Neurol Sci       Date:  2022-07-18       Impact factor: 3.830

Review 3.  CD40-CD40L in Neurological Disease.

Authors:  Heather D Ots; Jovanna A Tracz; Katherine E Vinokuroff; Alberto E Musto
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

4.  Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts.

Authors:  C M Gelbmann; S N Leeb; D Vogl; M Maendel; H Herfarth; J Schölmerich; W Falk; G Rogler
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

5.  Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells.

Authors:  Jun Wu; Xiao Yang; Yun-Fang Zhang; Shu-Feng Zhou; Rui Zhang; Xiu-Qing Dong; Jin-Jin Fan; Mei Liu; Xue-Qing Yu
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

6.  Thyrotropin and CD40L Stimulate Interleukin-12 Expression in Fibrocytes: Implications for Pathogenesis of Thyroid-Associated Ophthalmopathy.

Authors:  Tong Wu; Tünde Mester; Shivani Gupta; Fengyuan Sun; Terry J Smith; Raymond S Douglas
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

Review 7.  Cannabinoids and neuroinflammation.

Authors:  Lisa Walter; Nephi Stella
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

Review 8.  Future innovations in anti-platelet therapies.

Authors:  N E Barrett; L Holbrook; S Jones; W J Kaiser; L A Moraes; R Rana; T Sage; R G Stanley; K L Tucker; B Wright; J M Gibbins
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 9.  Understanding the pathogenesis of Kawasaki disease by network and pathway analysis.

Authors:  Yu-wen Lv; Jing Wang; Ling Sun; Jian-min Zhang; Lei Cao; Yue-yue Ding; Ye Chen; Ji-juan Dou; Jie Huang; Yi-fei Tang; Wen-tao Wu; Wei-rong Cui; Hai-tao Lv
Journal:  Comput Math Methods Med       Date:  2013-03-06       Impact factor: 2.238

10.  A20 overexpression inhibits lipopolysaccharide-induced NF-κB activation, TRAF6 and CD40 expression in rat peritoneal mesothelial cells.

Authors:  Xun-Liang Zou; De-An Pei; Ju-Zhen Yan; Gang Xu; Ping Wu
Journal:  Int J Mol Sci       Date:  2014-04-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.